Skip to content
US AU UK/EU CA
general@orthocell.com +61 8 9360 2888
About
Team
Solutions
Remplir
Striate+
Cell Therapies
Invest
News
Contact
Practitioners
Remplir
Striate+
OrthoATI
OrthoACI
Patients
Remplir
Striate+
OrthoATI
OrthoACI
About
Team
Solutions
Remplir
Striate+
Cell Therapies
Invest
News
Contact
Practitioners
Remplir
Striate+
OrthoATI
OrthoACI
Patients
Remplir
Striate+
OrthoATI
OrthoACI
We detected you're visiting from Australia. Would you like to switch to the AU version of this site?

Author: scott forrest

Media

Orthocell has positive tennis elbow result

Orthocell has been featured in The Australian’s Business Spectator, following the release of new positive results from a study of our tendon cell treatment for tennis elbow. 

by scott forrest
October 29, 2015
Media

Funding boost for tendon research

The Australian has featured news of Orthocell’s Australian Research Council grant to continue its tendon research.

by scott forrest
July 9, 2015
Media

Patent success a good sign for Orthocell

Following our recent patent announcement, the Australian Financial Review has featured Orthocell in its Market Wrap.

by scott forrest
September 30, 2014
Media

Strong demand for biotech

The Australian newspaper has featured news of Orthocell’s listing on the ASX. 

by scott forrest
July 23, 2014
Media

Biotech Orthocell looks to raise $8m in IPO

Details of Orthocell’s upcoming launch on the ASX has been featured in the Australian Financial Review (AFR).

by scott forrest
June 10, 2014
Media

Orthocell to list on ASX

Orthocell’s plans to list on the Australian Stock Exchange (ASX) have been featured in The Australian newspaper. 

by scott forrest
May 29, 2014
Media

Stem cells show promise mending busted tendons

Jill Margo, Health Editor at the Australian Financial Review, has published a feature article on Orthocell’s innovative autologous tenocyte implantation (ATI) therapy.

by scott forrest
June 30, 2011

Posts navigation

Newer posts
  • Search

  • Categories

    • ASX Announcements
    • Audio
    • Clinical Stories
    • Company News
    • Evidence
    • Media
    • Patient Stories
    • Video
  • Recent Posts

    • Orthocell achieves first Remplir™ sales in US$75 million Canadian Market
    • Remplir™ RWE study delivers 90% success rate
    • Orthocell reports continued growth and strong US momentum in March 2026 quarter
    • First Remplir™ Surgical Case Completed in U.S. Department of Defense Hospital Network 
    • Orthocell secures Remplir™ approval across U.S. Department of Defence Hospital Network
  • Explore Orthocell Ltd →

    © Orthocell Ltd. All rights reserved. ABN: 57 118 897 135

    +61 8 9360 2888
    general@orthocell.com
    AU